GlassScriptPhysician profile
Suchithra Nancherla
NPI 1851312995
$1,551.40
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $39.62 · 2021: $60.92 · 2022: $97.37 · 2023: $434 · 2024: $57.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441 · Education: $50.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $440.98 |
| Education | $50.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $372.26 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $170.25 | 2019-2024 | Mounjaro, Zepbound |
| Amgen INC. | $164.72 | 2019-2024 | Evenity, Prolia, Tepezza |
| Tandem Diabetes Care, INC. | $136.31 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $116.70 | 2019 | |
| Acella Pharmaceuticals, LLC | $88.59 | 2023 | NP Thyroid 60 |
| Exelixis INC. | $87.32 | 2023 | Cabometyx |
| Xeris Pharmaceuticals, INC. | $68.87 | 2022-2023 | Recorlev |
| Novo Nordisk INC | $65.59 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.53 | 2019 | |
| Pfizer INC. | $42.01 | 2022-2023 | |
| Abbott Laboratories | $34.50 | 2022-2024 | Freestyle Libre 3 |
| Insulet Corporation | $26.53 | 2023 | Omnipod |
| Antares Pharma, INC. | $23.64 | 2020 | |
| Dexcom, INC. | $21.33 | 2023 | Dexcom G7 Gss (161) |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $20.21 | 2023 | |
| Beta Bionics, INC. | $19.08 | 2023 | Ilet Bionic Pancreas |
| Medtronic Minimed, INC. | $15.98 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.98 | 2023 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suchithra Nancherla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.